|
⚲
|
| Keyboard |
| Samuel Waksal | |
|---|---|
| Firm | |
| Address | c/o Graviton Bioscience Corporation 125 West End Ave, Suite 301 New York, NY 10023 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| Graviton Bioscience Corp | 021-505280 | Executive Officer | 25.0 M of 25.0 M |
||
| Graviton Bioscience Corp | 021-498756 | Executive Officer | 25.0 M of 25.0 M |
||
| Graviton Bioscience Corp | 021-498757 | Executive Officer | 39.8 M of 50.0 M |
||
| Equilibre Biopharmaceuticals Corp | 021-430166 | Executive Officer | 15.9 M of 25.0 M |
||
| Graviton Bioscience Corp | 021-389955 | Director | 3.5 M of 30.0 M |
||
| Kadmon Holdings LLC | 021-222099 | Executive Officer | 5.7 M of 50.0 M |
||
| Kadmon Holdings LLC | 021-183475 | Executive Officer | 4.7 M of 50.0 M |
||
| Kadmon I LLC | 021-145358 | Executive Officer | 10.8 M of 50.0 M |
||